Qsemble Capital Management LP Purchases New Stake in Insmed Incorporated (NASDAQ:INSM)

Qsemble Capital Management LP acquired a new position in shares of Insmed Incorporated (NASDAQ:INSM) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 23,155 shares of the biopharmaceutical company’s stock, valued at approximately $1,690,000.

Several other institutional investors have also recently bought and sold shares of the business. V Square Quantitative Management LLC bought a new position in Insmed in the 3rd quarter valued at about $30,000. EntryPoint Capital LLC purchased a new position in shares of Insmed during the first quarter valued at approximately $33,000. GAMMA Investing LLC boosted its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter.

Insmed Price Performance

Insmed stock opened at $74.09 on Tuesday. The firm has a market capitalization of $13.25 billion, a P/E ratio of -13.35 and a beta of 1.12. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business has a fifty day moving average price of $72.05 and a 200-day moving average price of $66.93.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the prior year, the firm posted ($1.10) earnings per share. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. As a group, equities research analysts forecast that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Activity

In other news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. The trade was a 11.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 27.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on INSM. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. StockNews.com downgraded Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. UBS Group boosted their price objective on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. TD Cowen lifted their target price on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Bank of America increased their price target on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.